Most people with spinal cord injury are paralyzed from the injury site down, even when the cord isn't completely severed. Why don't the spared portions of the spinal cord keep working? Researchers now provide insight into why these nerve pathways remain quiet. They also show that a small-molecule compound, given systemically, can revive these circuits in paralyzed mice, restoring their ability to walk. The study was published in the journal Cell.
"For this fairly severe type of spinal cord injury, this is most significant functional recovery we know of," says the senior author. "We saw 80 percent of mice treated with this compound recover their stepping ability."
Many animal studies looking to repair spinal cord damage have focused on getting nerve fibers, or axons, to regenerate, or to getting new axons to sprout from healthy ones. While impressive axon regeneration and sprouting have been achieved, by the lab and others, their impacts on the animals' motor function after a severe injury are less clear. Some studies have tried using neuromodulators such as serotonergic drugs to simulate the spinal circuits, but have gotten only transient, uncontrolled limb movement.
The authors took another approach, inspired by the success of epidural electrical stimulation-based strategies, the only treatment known to be effective in patients with spinal cord injury. This treatment applies a current to the lower portion of the spinal cord; combined with rehabilitation training, it has enabled some patients to regain movement.
"Epidural stimulation seems to affect the excitability of neurons," says the senior author. "However, in these studies, when you turn off the stimulation, the effect is gone. We tried to come up with a pharmacologic approach to mimic the stimulation and better understand how it works."
The researchers selected a handful of compounds that are already known to alter the excitability of neurons, and are able to cross the blood-brain barrier. They gave each compound to paralyzed mice in groups of 10 via intraperitoneal injection. All mice had severe spinal cord injury, but with some nerves intact. Each group (plus a control group given placebo) was treated for eight to ten weeks.
One compound, called CLP290, had the most potent effect, enabling paralyzed mice to regain stepping ability after four to five weeks of treatment. Electromyography recordings showed that the two relevant groups of hindlimb muscles were active. The animals' walking scores remained higher than the controls' up to two weeks after stopping treatment. Side effects were minimal.
CLP290 is known to activate a protein called KCC2, found in cell membranes, that transports chloride out of neurons. The new research shows that inhibitory neurons in the injured spinal cord are crucial to recovery of motor function. After spinal cord injury, these neurons produce dramatically less KCC2. As a result, the authors found, they can't properly respond to signals from the brain. Unable to process inhibitory signals, they respond only to excitatory signals that tell them to keep firing. And since these neurons' signals are inhibitory, the result is too much inhibitory signaling in the overall spinal circuit. In effect, the brain's commands telling the limbs to move aren't relayed.
By restoring KCC2, with either CLP290 or genetic techniques, the inhibitory neurons can again receive inhibitory signals from the brain, so they fire less. This shifts the overall circuit back toward excitation, the researchers found, making it more responsive to input from the brain. This had the effect of reanimating spinal circuits disabled by the injury.
The researchers are now investigating other compounds that act as KCC2 agonists. They believe such drugs, or perhaps gene therapy to restore KCC2, could be combined with epidural stimulation to maximize a patient's function after spinal cord injury.
https://www.cell.com/cell/fulltext/S0092-8674(18)30730-X
Latest News
Disulfide disruption reverses mucus dysfunction in asthma
Reverse engineering 3D chromosome models for individual cells
Imagining a face reactivates face-detecting neurons in humans
Local immune response to food antigens drives meal-induced abdominal pain
Spliceosome targeted therapy in triple negative breast cancer
Other Top Stories
Gene therapy restores vision in blind mice
A master regulator of regeneration identified!
Serotonylation of histones to regulate gene expression
Epigenetic marks on sperm chromosomes affect gene expression and development in offspring
Gene interactions in cells
Protocols
Dual-Angle Protocol for Doppler Optical Coherence Tomography to Improve Retinal Blood Flow Measur…
Detection of protein SUMOylation in vivo
In vivo analysis of protein sumoylation induced by a viral protein: Detection of HCMV pp71-induce…
Determination of SUMOylation sites
miR-Selection 3'UTR Target Selection Kit
Publications
Delayed maturation of the structural brain connectome in neonates with congenital heart disease
Disulfide disruption reverses mucus dysfunction in allergic airway disease
Frequent neurocognitive deficits after recovery from mild COVID-19
High-resolution single-cell 3D-models of chromatin ensembles during Drosophila embryogenesis
Face-selective units in human ventral temporal cortex reactivate during free recall
Presentations
Homeostasis
PLANT MITOCHONDRIAL BIOLOGY
Photosynthesis
Endocrine Disorders
THE PITUITARY GLAND
Posters
ACMT 2020 Annual Scientific Meeting Abstracts - New York, NY
Abstracts from the 2020 Annual Scientific Meeting of the British and Irish Hypertension Society (…
ACNP 58th Annual Meeting: Poster Session III
ACNP 58th Annual Meeting: Poster Session II
ACNP 58th Annual Meeting: Poster Session I